TESARO (NASDAQ:TSRO)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Friday. They presently have a $158.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 127.04% from the stock’s current price.
The analysts wrote, “Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration.””
Several other brokerages also recently commented on TSRO. Robert W. Baird reiterated a “neutral” rating and set a $125.00 price target on shares of TESARO in a report on Monday, October 2nd. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Piper Jaffray Companies reiterated a “neutral” rating and set a $117.00 price target on shares of TESARO in a report on Monday, October 23rd. Finally, Barclays assumed coverage on shares of TESARO in a report on Monday, October 23rd. They set an “equal weight” rating and a $135.00 price target on the stock. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. TESARO has an average rating of “Hold” and an average target price of $152.64.
Shares of TESARO (NASDAQ TSRO) opened at $69.59 on Friday. TESARO has a fifty-two week low of $69.38 and a fifty-two week high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34. The firm has a market cap of $3,784.44, a PE ratio of -8.25 and a beta of 1.51.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.69. The company had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm’s revenue was up 740.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.72) EPS. research analysts anticipate that TESARO will post -8.19 earnings per share for the current year.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a filing with the SEC, which is available through this link. 34.60% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in TSRO. Exane Derivatives purchased a new stake in shares of TESARO in the 3rd quarter worth approximately $106,000. Nordea Investment Management AB purchased a new stake in shares of TESARO in the 2nd quarter worth approximately $167,000. Oppenheimer Asset Management Inc. lifted its position in shares of TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares during the period. Toronto Dominion Bank lifted its position in shares of TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares during the period. Finally, Commonwealth Equity Services Inc purchased a new stake in shares of TESARO in the 3rd quarter worth approximately $222,000.
WARNING: This article was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/tesaro-tsro-rating-reiterated-by-hc-wainwright.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.